CooperCompanies stock gains 1.41 percent after guidance reset

Published on 09/24/2026 at 12:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CooperCompanies stock posted fiscal Q3 revenue of USD 1.066 billion, up 1 percent year over year on September 9. JPMorgan cut its target to USD 58.

Reinraum-Produktionsanlage für medizinische Geräte mit Technikern an Kontaktlinsen-Fertigungslinien — CooperCompanies Reinraum-Produktion US21664P1039 zeigt automatisierte Kontaktlinsen-Fertigungslinien mit optischer Qualitätsprüfung im sterilen Reinraumbereich, Illustration mit AI erstellt.

CooperCompanies stock (ISIN US2166485019) gained 1.41 percent to USD 56.07 on Nasdaq on September 23, 2026, after a sharp September selloff triggered by weaker guidance. The medical device company reported fiscal third-quarter revenue of USD 1.066 billion for the period ended July 31, 2026.

Revenue growth stayed modest

CooperCompanies said on September 9, 2026, that third-quarter revenue rose 1 percent year over year and 1 percent organically. CooperVision contributed USD 717.0 million, while CooperSurgical generated USD 349.2 million, up 2 percent on a reported basis and 3 percent organically.

The earnings mix was unusually sensitive to one-off effects. GAAP diluted EPS reached USD 2.24 in fiscal Q3 2026, while adjusted diluted EPS was USD 1.15, and net income included a USD 307.2 million discrete tax benefit tied to a favorable U.K. tax examination.

Analysts cut targets after guidance

The company guided to fiscal fourth-quarter revenue of USD 1.057 billion to USD 1.080 billion and full-year fiscal 2026 revenue of USD 4.229 billion to USD 4.252 billion. Fourth-quarter non-GAAP diluted EPS guidance was USD 1.05 to USD 1.09, putting the next quarter's earnings range below the fiscal third-quarter adjusted EPS figure of USD 1.15.

JPMorgan lowered its price target from USD 71 to USD 58 while keeping a neutral rating, according to MarketBeat on September 10, 2026. The target revision shows why the stock reaction has centered on forward earnings rather than the tax-enhanced GAAP result.

Buyback adds a second signal

CooperCompanies completed its strategic review and chose to retain CooperSurgical, while its board expanded the share repurchase authorization from USD 2 billion to USD 3 billion, according to StockTitan. The capital-allocation decision gives the valuation debate a second axis, but contact-lens demand remains the immediate operating issue.

Stock remains below yearly high

CooperCompanies stock was trading at USD 56.07 on Nasdaq on September 23, 2026, with a market capitalization of USD 10.935 billion. The 52-week range was USD 51.01 to USD 89.83, leaving the price USD 33.76 below the yearly high and USD 5.06 above the low.